The Receptor Affinity and Chemistry of Bufotenin and Bufotenidine

Don't be confused by the similar spelling and chemical structure. These are two very distinct compounds.


The compounds bufotenin and bufotenidine may have similar spellings and look alike at first glance, but they differ in their receptor affinity and chemistry. Comparing these molecules is a good example of how seemingly small changes in chemical structure cause big effects in function.


Bufotenin (also known as 5-HO-DMT) is a toxin discovered in the secretions of the toad Bufo vulgaris.1 Its chemical structure was confirmed in 1934.2 In 1935, Hoshino and Shimodaria were the first to synthesize it.3 Studies indicate that people suffering from schizophrenia often have detectable levels of bufotenin in their brains, urine, and plasma.4–6 Also, nature reveals bufotenin in other organisms like frogs, plants, mammals, and mushrooms.

The serotonin receptors are the main site of action for bufotenin and bufotenidine. In particular, their psychoactive properties are due to their potent agonist activity at the 5-HT2A receptor.7 Further, studies indicate that both compounds bind to other serotonin receptors including 5-HT1A and 5-HT1B,8 and 5-HT3.9


Bufotenidine (also called 5-HTQ or cinobufagin) is the trimethylammonium salt of bufotenin.10 Like bufotenin, bufotenidine is a toxin, but it is a selective agonist of the serotonin 5-HT3 receptor.11 In nature, bufotenidine is found in some of the same places as bufotenin such as frog skin12 and plants.13

Because it is an agonist of the 5-HT3 receptor, bufotenidine is used in scientific research to study the function of this receptor. Also, traditional Chinese medicine (Chan Su) is using toad secretions containing bufotenidine to treat pain in cancer patients.14,15  Research has shown that the addition of a third methyl group to the ammonium ion (compared to bufotenin) prevents bufotenidine from crossing the blood-brain barrier.14 This explains bufotenidine’s ability to alleviate pain via the peripheral nervous system. However, this barrier also prevents its use in 5-HT3 receptor studies in the brain and other areas of the central nervous system.

Comparison of the Molecular Structures

Bufotenin and bufotenidine (Figure 1) are two compounds that have a chemical structure similar to psilocin and psilocybin (Figure 2). Bufotenin and bufotenidine differ by a single methyl group—two versus three. Notice that bufotenin is psilocin with the hydroxy group at the 5-position instead of the 4-position. In contrast, bufotenidine is bufotenin with a trimethylammonium group instead of a dimethylamine group (students of psilocybin derivatives will notice that bufotenidine is dephosphorylated aeruginascin with the HO- group at the 5-position instead of the 4-position).

Figure 1: Bufotenin and bufotenidine are close structural analogs of psilocybin and psilocin (Figure 2).

Figure 2: Psilocybin and psilocin are two different compounds found in magic mushrooms. Our current understanding is that psilocybin is minimally active in the body and is rapidly converted into psilocin which is the active metabolite.

The Role of Dephosphorylation

It is interesting to note that bufotenin and bufotenidine do not have a phosphate group like psilocybin. In the case of bufotenidine, it is unknown if a phosphorylated version exists which would undergo dephosphorylation by the body into the active molecule.

The body dephosphorylates psilocybin to psilocin which is the metabolically active form. Phosphorylated versions of molecules like psilocybin are considered prodrugs of their dephosphorylated counterparts. Like bufotenidine, a phosphorylated version of bufotenin is not known. This creates the opportunity for answering intriguing research questions about the metabolic pathway for the synthesis of bufotenin and bufotenidine in toads, plants, and other living things.


It is clear that the differences between a dimethylamine group and a trimethylammonium group affect the pharmacology of bufotenin and bufotenidine. However, just like psilocybin and psilocin, a lot of mystery surrounds these compounds and how they work in the human body. For more information on bufotenin and bufotenidine, see the book Anadenanthera: Visionary Plant of Ancient South America.16

Barb Bauer Headshot

Barb is the former Editor and one of the founders of Psychedelic Science Review. She is currently a contributing writer. Her goal is making accurate and concise psychedelic science research assessable so that researchers and private citizens can make informed decisions.


Notify of

Inline Feedbacks
View all comments
  1. Handovsky H. Ein alkaloid im gifte von Bufo vulgaris. Naunyn-Schmiedeberg’s Archives of Pharmacology. 1920;86(1):138-158. doi:10.1007/BF01864237
  2. Wieland H, Konz W, Mittasch H. Die Konstitution von Bufotenin und Bufotenidin. Über Kröten-Giftstoffe. VII. Justus Liebigs Annalen der Chemie. 1934;513(1):1-25. doi:10.1002/jlac.19345130102
  3. Hoshino T, Shimodaira K. Synthese des Bufotenins und über 3-Methyl-3-β-oxyäthyl-indolenin. Synthesen in der Indol-Gruppe. XIV. Justus Liebigs Annalen der Chemie. 1935;520(1):19-30. doi:10.1002/jlac.19355200104
  4. Kärkkäinen J, Räisänen M, Naukkarinen H, Spoov J, Rimon R. Urinary excretion of free bufotenin by psychiatric patients. Biological Psychiatry. 1988;24(4):441-446. doi:10.1016/0006-3223(88)90182-5
  5. Narasimhachari N, Himwich HE. GC-MS identification of bufotenin in urine samples from patients with schizophrenia or infantile autism. Life Sciences. 1973;12(10, Part 2):475-478. doi:10.1016/0024-3205(73)90335-4
  6. Takeda N, Ikeda R, Ohba K, Kondo M. Bufotenine reconsidered as a diagnostic indicator of psychiatric disorders. Neuroreport. 1995;6(17):2378-2380. Accessed March 2, 2019.
  7. Egan C, Grinde E, Dupre A, et al. Agonist high and low affinity state ratios predict drug intrinsic activity and a revised Ternary complex mechanism at serotonin 5-HT2A and 5-HT2C receptors. Synapse. 2000;35(2):144-150. doi:10.1002/(SICI)1098-2396(200002)35:2<144::AID-SYN7>3.0.CO;2-K
  8. Peroutka SJ, Ison PJ, Liu DU, Barrett RW. Artifactual High-Affinity and Saturable Binding of [3H]5-Hydroxytryptamine Induced by Radioligand Oxidation. Journal of Neurochemistry. 1986;47(1):38-45. doi:10.1111/j.1471-4159.1986.tb02828.x
  9. Milburn CM, Peroutka SJ. Characterization of [3H]Quipazine Binding to 5-Hydroxytryptamine3 Receptors in Rat Brain Membranes. Journal of Neurochemistry. 1989;52(6):1787-1792. doi:10.1111/j.1471-4159.1989.tb07258.x
  10. Shulgin A, Shulgin A. TiHKAL: The Continuation. First Edition. Berkeley, California: Transform Press; 2002.
  11. Kilpatrick GJ, Bunce KT, Tyers MB. 5-HT3 receptors. Medicinal Research Reviews. 1990;10(4):441-475. doi:10.1002/med.2610100404
  12. Dai Y-H, Shen B, Xia M-Y, et al. A New Indole Alkaloid from the Toad Venom of Bufo bufo gargarizans. Molecules. 2016;21(3):349. doi:10.3390/molecules21030349
  13. Servillo L, Giovane A, Balestrieri ML, Casale R, Cautela D, Castaldo D. Citrus genus plants contain N-methylated tryptamine derivatives and their 5-hydroxylated forms. J Agric Food Chem. 2013;61(21):5156-5162. doi:10.1021/jf401448q
  14. Chen T, Hu W, He H, et al. A Study on the Mechanism of Cinobufagin in the Treatment of Paw Cancer Pain by Modulating Local β-Endorphin Expression In Vivo. Evidence-Based Complementary and Alternative Medicine. 2013. doi:10.1155/2013/851256
  15. Chen T, Yuan S, Wan X, et al. Chinese herb cinobufagin-reduced cancer pain is associated with increased peripheral opioids by invaded CD3/4/8 lymphocytes. Oncotarget. 2016;8(7):11425-11441. doi:10.18632/oncotarget.14005
  16. Torres CM, Repke DB. Anadenanthera: Visionary Plant of Ancient South America. 1 edition. New York: Routledge; 2006.